Abstract 52P
Background
We evaluated the relationship between 18F-FDG uptake and mitochondrial activity in cancer cells and investigated the prognostic implications thereof in patients with invasive ductal carcinoma of the breast (IDCB).
Methods
In total, 150 consecutive patients with IDCB who underwent preoperative 18F-FDG PET/CT followed by curative surgical resection were retrospectively enrolled. Mitochondrial activity of cancer cells was assessed based on translocase of outer mitochondrial membrane 20 (TOMM20) expression and cytochrome C oxidase (COX) activity. Pearson’s correlation analysis was used to assess the relationship between SUVmax of the primary tumour (pSUVmax) and mitochondrial activity. Clinicopathological factors, including pSUVmax, histological grade, expression of ER, PR, HER2, and TOMM20, and COX activity, were assessed for prediction of progression-free survival (PFS). The Kaplan–Meier method and Cox proportional hazards model were used for the survival analysis.
Results
Sixteen of the 150 subjects (10.7%) showed progression during the follow-up period. pSUVmax correlated significantly and positively with TOMM20 expression and COX activity. Univariate analysis revealed that pSUVmax, TOMM20 expression, COX activity, ER and PR status, and histologic grade were significantly associated with PFS. Multivariate analysis revealed a significant difference in pSUVmax (HR, 4.50; 95% CI, 1.43–14.17; P = 0.010).
Conclusions
There was a significant positive correlation between 18F-FDG uptake and mitochondrial activity of cancer cells in patients with IDCB. Increased 18F-FDG uptake and mitochondrial activity were significantly associated with a shorter PFS. Therefore, assessment of preoperative 18F-FDG uptake and post-surgical mitochondrial activity in patients with IDCB could be used as marker for prediction of PFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Choi Byung Wook (Daegu Catholic University Medical Center).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract